References
- National Cancer Institute SEER Stat Fact Sheets: Acute myeloid leukemia. Available from: http://seer.cancer.gov/statfacts/html/amyl.html [cited 2013 Sep 30].
- Taylor PRA, Reid MM, Stark AN, Bown N, Hamilton PJ, Proctor SJ, et al. De novo acute myeloid leukemia in patients over 55-years-old: A population-based study of incidence, treatment and outcome. Leukemia 1995; 9:231–7.
- Ostgård LS, Kjeldsen E, Holm MS, Brown Pde N, Pedersen BB, Bendix K, et al. Reasons for treating secondary AML as de novo AML. Eur J Haematol 2010; 85:217–26.
- Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Björkholm M. Improved patient survival for acute myeloid leukemia: A population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009;113:3666–72.
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
- Available from: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf [cited 2013 Sep 30].
- Åsa RD, Sigurdur YK, Therese ML. A. Improved patient survival for acute myeloid leukemia: A population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009;113:3666–72.
- Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica 2008;93:594–600.
- Available from: http://seer.cancer.gov/data/metadata.html [cited 2014 Jan 20].
- Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179–87.
- Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009;27:61–9.
- Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249–59.
- Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009;27:5397–403.
- Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR, et al. Outcome of older patients with acute myeloid leukemia: An analysis of SEER data over 3 decades. Cancer 2013; 119:2720–7.